NDATOPICALDISC
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMLA is a topical anesthetic disc containing lidocaine and prilocaine in a eutectic mixture, designed for rapid skin numbing. It provides localized anesthesia by blocking sodium channels in nerve fibers. The product is used primarily for pain relief during minor medical procedures, vaccinations, and dermatological interventions.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30/100), the team is likely focused on lifecycle extension and defending market position against generic entrants.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
Started Sep 2024
164 enrolled
Tourette Syndrome
A Study to Assess Therapeutic Equivalence Between Test EMLA Patch With Marketed EMLA Patch in Healthy Subjects.
Started Oct 2017
32 enrolled
Pain
Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children
Started Sep 2012
66 enrolled
Lumbar PunctureTopical Analgesia
Career Relevance
Working on EMLA offers experience in managing a mature, high-volume topical anesthetic product in a competitive environment. The approaching LOE phase provides exposure to lifecycle management, generic defense strategies, and organizational planning for market transitions.
Worked on EMLA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.